PRMT5-MTA-IN-8 

PRMT5-MTA-IN-8 is an orally active PRMT5-MTA complex inhibitor (IC₅₀ = 4.4 nM). PRMT5-MTA-IN-8 inhibits the intracellular production of symmetric dimethylarginine (SDMA) as well as the proliferation of MTAP-deficient cells. PRMT5-MTA-IN-8 exerts antitumor efficacy by inhibiting PRMT5, reducing SDMA levels and inducing tumor cell apoptosis in mouse models of triple-negative breast cancer. PRMT5-MTA-IN-8 can be used in research related to cancers such as triple-negative breast cancer^[1].

PRMT5-MTA-IN-8 (Compound I-14) inhibits PRMT5-dependent SDMA formation in HCT116 MTAP-null cells (IC₅₀ = 0.8 nM) and suppresses the proliferation of HCT116 MTAP-null cells (IC₅₀ = 3.9 nM)^[1].
PRMT5-MTA-IN-8 (0.1-1000 nM, 6 days) inhibits PRMT5-dependent SDMA production in MDA-MB-231 cells with an IC₅₀ of 0.25 nM, and increases the thermal stability of PRMT5^[1].
PRMT5-MTA-IN-8 exhibits high metabolic stability in rat liver microsomes and plasma, with half-lives of 131 and 136 min, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PRMT5-MTA-IN-8 (I-14) (25-100 mg/kg; p.o.; daily; 28 days) exerts antitumor efficacy in the MDA-MB-231 TNBC xenograft model through targeted inhibition of PRMT5, reduction of SDMA levels, and induction of tumor cell apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

441.28

C₁₉H₁₇BrN₆O₂

3105952-57-3

CON(CC1=CC=C(C=N1)Br)C(C2=CC=C(C3=C2)N=C(C4=C3N(N=C4)C)N)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cheng X, et al. Discovery of Oxime Ether Derivatives as Second-Generation PRMT5 Inhibitors for the Treatment of Triple Negative Breast Cancer. J Med Chem. 2026;69(3):2647-2665.  [Content Brief]